Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. Two ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...

Therapeutics announced that the U.S. FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and ...

US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...

Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. The business had revenue of $24.12 million during the quarter, compared to analyst estimates of ...

Nektar (NKTR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...

In a recent filing with the Securities and Exchange Commission, Nektar Therapeutics (NASDAQ:NKTR) disclosed a significant change in its senior leadership team. The announcement comes as the ...

Nektar (NKTR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall ...

In a recent filing with the Securities and Exchange Commission, Nektar Therapeutics (NASDAQ:NKTR) disclosed a significant change in its senior leadership team. The announcement comes as the company, ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...